Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02759640
Other study ID # HS-10241-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2016
Est. completion date May 2018

Study information

Verified date February 2019
Source Atridia Pty Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.


Description:

Recently, c-Met has become an important target of intensive research in search of specific inhibitors as potential new therapies for cancers driven by c-Met activation. HS-10241 is a potent and selective small molecule c-Met kinase inhibitor for both enzyme and c-Met phosphorylation in the cell. Consistent with its potent enzyme and cell activity, HS-10241 was found to inhibit cell growth in vitro against tumors with c-Met gene amplification or c-Met overexpression. On the basis of these findings, the current trial will be conducted in participants with advanced solid tumors for whom standard treatment is not currently available. This study consists of 2 phases. In the dose-escalation phase, up to 5 dose levels of HS-10241 (100 mg/day, 200 mg/day, 340 mg/day, 500 mg/day, and 700 mg/day) will be investigated with a sequential "3+3" design (3 or 6 participants in every dose level). Participants will have a single-dose pharmacokinetic (PK) run-in period (7 days). Following the first dose, participants will enter a 1 week treatment-free period to evaluate safety and single-dose PK. If no dose-limiting toxicities (DLTs) are observed during the 1-week period, HS-10241 administration will resume at the same dose level. In the expansion phase, up to 12 additional participants will be enrolled at the MTD. Anti-tumor effects will be assessed every 2 cycles (4 weeks=1 cycle) by using RECIST version 1.1 criteria.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date May 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. At least 18 years of age 2. Ability to understand the purposes and risks of the trial and his/her informed consent using the Human Research Ethics Committee (HREC) approved informed consent form (ICF). 3. Histologically or cytologically confirmed advanced or metastatic solid tumor for which standard therapy does not exist, has failed, or has been refused. 4. Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia) 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Life expectancy of at least 3 months 7. Acceptable liver function defined below: - Total bilirubin = 2 times upper limit of normal range (ULN) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 times ULN; however, =5 times ULN in a subject who has liver metastases 8. Acceptable renal function defined below: - Serum creatinine =1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) =60 mL/minutes 9. Acceptable coagulation status defined below: - Prothrombin time <1.5 times ULN - Partial thrombin time <1.5 times ULN 10. Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below: - Absolute neutrophil count (ANC) =1500/µL - Platelet count =100000/µL - Hemoglobin =9.0 g/dL 11. No clinically significant abnormalities in urinalysis 12. All participants must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an intrauterine device) with their partner from entry into the trial through 6 months after the last dose. Exclusion Criteria: 1. Hematologic malignancies 2. Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease 3. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy 4. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery 5. Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris 6. Seizure disorders requiring anticonvulsant therapy 7. Taking a medication that prolongs QT interval and has a risk of Torsade de Pointes, or a history of long QT syndrome 8. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product 9. Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry. Ongoing androgen deprivation therapy or bisphosphonates are allowed. 10. Participation in an investigational drug or device trial within 4 weeks prior to the trial entry 11. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C 12. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of trial entry) 13. History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis; 14. Subject is pregnant (positive serum beta human chorionic gonadotropin [ß-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment 15. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial 16. History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation 17. Unwillingness or inability to comply with the trial protocol for any reason 18. Legal incapacity or limited legal capacity 19. Known drug abuse or alcohol abuse 20. Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9. Patients are eligible if these medications can be stopped or substituted within the screening period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HS-10241
HS-10241 is administered orally starting at 100 mg/day.

Locations

Country Name City State
Australia Chris O'Brien Lifehouse Camperdown New South Wales
Australia Liverpool Liverpool New South Wales

Sponsors (1)

Lead Sponsor Collaborator
Atridia Pty Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) MTD is defined as the maximum dose level at which no more than 1 out of 3 participants experience a DLT within the first 4 weeks of multiple dosing. 4 weeks
Secondary Number of participants with treatment-emergent adverse events (TEAEs) 24 months
Secondary Peak plasma concentration (Cmax) 4 weeks
Secondary Area under the plasma concentration-time curve (AUC) 4 weeks
Secondary T1/2 (half-life) 4 weeks
Secondary Objective response rate (ORR) 24 months
Secondary Time to reach maximum plasma concentration (Tmax) 4 weeks
Secondary Clearance (CL) 4 weeks
Secondary Volume of distribution at steady state (Vss) 4 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00750841 - Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours Phase 1
Withdrawn NCT05419817 - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Phase 2
Completed NCT02828930 - A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) Phase 1
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Terminated NCT03225105 - M3541 in Combination With Radiotherapy in Solid Tumors Phase 1
Completed NCT03258515 - A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers Phase 1
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Completed NCT01878890 - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. Phase 1
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT03634982 - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Phase 1
Recruiting NCT04685226 - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT06036121 - A Study of ADRX-0706 in Select Advanced Solid Tumors Phase 1
Active, not recruiting NCT03258151 - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed NCT01528046 - Metformin in Children With Relapsed or Refractory Solid Tumors Phase 1
Recruiting NCT05325866 - A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Withdrawn NCT01940601 - Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors Phase 2
Completed NCT02279433 - A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Phase 1